Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.
Identifieur interne : 000C87 ( PubMed/Corpus ); précédent : 000C86; suivant : 000C88Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.
Auteurs : Heimo Lagler ; Katharina Grabmeier-Pfistershammer ; Veronique Touzeau-Römer ; Selma Tobudic ; Michael Ramharter ; Judith Wenisch ; Guido Andrés Gualdoni ; Monika Redlberger-Fritz ; Theresia Popow-Kraupp ; Armin Rieger ; Heinz BurgmannSource :
- PloS one [ 1932-6203 ] ; 2012.
English descriptors
- KwdEn :
- Adult, Female, HIV Infections (complications), HIV Infections (immunology), Hemagglutination Inhibition Tests, Humans, Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (adverse effects), Influenza Vaccines (immunology), Influenza, Human (complications), Influenza, Human (immunology), Influenza, Human (prevention & control), Male, Middle Aged, Prospective Studies.
- MESH :
- chemical , adverse effects : Influenza Vaccines.
- complications : HIV Infections, Influenza, Human.
- immunology : HIV Infections, Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Influenza, Human.
- prevention & control : Influenza, Human.
- Adult, Female, Hemagglutination Inhibition Tests, Humans, Male, Middle Aged, Prospective Studies.
Abstract
During the influenza pandemic of 2009/10, the whole-virion, Vero-cell-derived, inactivated, pandemic influenza A (H1N1) vaccine Celvapan® (Baxter) was used in Austria. Celvapan® is adjuvant-free and was the only such vaccine at that time in Europe. The objective of this observational, non-interventional, prospective single-center study was to evaluate the immunogenicity and tolerability of two intramuscular doses of this novel vaccine in HIV-positive individuals.
DOI: 10.1371/journal.pone.0036773
PubMed: 22629330
Links to Exploration step
pubmed:22629330Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.</title><author><name sortKey="Lagler, Heimo" sort="Lagler, Heimo" uniqKey="Lagler H" first="Heimo" last="Lagler">Heimo Lagler</name><affiliation><nlm:affiliation>Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Grabmeier Pfistershammer, Katharina" sort="Grabmeier Pfistershammer, Katharina" uniqKey="Grabmeier Pfistershammer K" first="Katharina" last="Grabmeier-Pfistershammer">Katharina Grabmeier-Pfistershammer</name></author><author><name sortKey="Touzeau Romer, Veronique" sort="Touzeau Romer, Veronique" uniqKey="Touzeau Romer V" first="Veronique" last="Touzeau-Römer">Veronique Touzeau-Römer</name></author><author><name sortKey="Tobudic, Selma" sort="Tobudic, Selma" uniqKey="Tobudic S" first="Selma" last="Tobudic">Selma Tobudic</name></author><author><name sortKey="Ramharter, Michael" sort="Ramharter, Michael" uniqKey="Ramharter M" first="Michael" last="Ramharter">Michael Ramharter</name></author><author><name sortKey="Wenisch, Judith" sort="Wenisch, Judith" uniqKey="Wenisch J" first="Judith" last="Wenisch">Judith Wenisch</name></author><author><name sortKey="Gualdoni, Guido Andres" sort="Gualdoni, Guido Andres" uniqKey="Gualdoni G" first="Guido Andrés" last="Gualdoni">Guido Andrés Gualdoni</name></author><author><name sortKey="Redlberger Fritz, Monika" sort="Redlberger Fritz, Monika" uniqKey="Redlberger Fritz M" first="Monika" last="Redlberger-Fritz">Monika Redlberger-Fritz</name></author><author><name sortKey="Popow Kraupp, Theresia" sort="Popow Kraupp, Theresia" uniqKey="Popow Kraupp T" first="Theresia" last="Popow-Kraupp">Theresia Popow-Kraupp</name></author><author><name sortKey="Rieger, Armin" sort="Rieger, Armin" uniqKey="Rieger A" first="Armin" last="Rieger">Armin Rieger</name></author><author><name sortKey="Burgmann, Heinz" sort="Burgmann, Heinz" uniqKey="Burgmann H" first="Heinz" last="Burgmann">Heinz Burgmann</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22629330</idno><idno type="pmid">22629330</idno><idno type="doi">10.1371/journal.pone.0036773</idno><idno type="wicri:Area/PubMed/Corpus">000C87</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C87</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.</title><author><name sortKey="Lagler, Heimo" sort="Lagler, Heimo" uniqKey="Lagler H" first="Heimo" last="Lagler">Heimo Lagler</name><affiliation><nlm:affiliation>Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Grabmeier Pfistershammer, Katharina" sort="Grabmeier Pfistershammer, Katharina" uniqKey="Grabmeier Pfistershammer K" first="Katharina" last="Grabmeier-Pfistershammer">Katharina Grabmeier-Pfistershammer</name></author><author><name sortKey="Touzeau Romer, Veronique" sort="Touzeau Romer, Veronique" uniqKey="Touzeau Romer V" first="Veronique" last="Touzeau-Römer">Veronique Touzeau-Römer</name></author><author><name sortKey="Tobudic, Selma" sort="Tobudic, Selma" uniqKey="Tobudic S" first="Selma" last="Tobudic">Selma Tobudic</name></author><author><name sortKey="Ramharter, Michael" sort="Ramharter, Michael" uniqKey="Ramharter M" first="Michael" last="Ramharter">Michael Ramharter</name></author><author><name sortKey="Wenisch, Judith" sort="Wenisch, Judith" uniqKey="Wenisch J" first="Judith" last="Wenisch">Judith Wenisch</name></author><author><name sortKey="Gualdoni, Guido Andres" sort="Gualdoni, Guido Andres" uniqKey="Gualdoni G" first="Guido Andrés" last="Gualdoni">Guido Andrés Gualdoni</name></author><author><name sortKey="Redlberger Fritz, Monika" sort="Redlberger Fritz, Monika" uniqKey="Redlberger Fritz M" first="Monika" last="Redlberger-Fritz">Monika Redlberger-Fritz</name></author><author><name sortKey="Popow Kraupp, Theresia" sort="Popow Kraupp, Theresia" uniqKey="Popow Kraupp T" first="Theresia" last="Popow-Kraupp">Theresia Popow-Kraupp</name></author><author><name sortKey="Rieger, Armin" sort="Rieger, Armin" uniqKey="Rieger A" first="Armin" last="Rieger">Armin Rieger</name></author><author><name sortKey="Burgmann, Heinz" sort="Burgmann, Heinz" uniqKey="Burgmann H" first="Heinz" last="Burgmann">Heinz Burgmann</name></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Female</term><term>HIV Infections (complications)</term><term>HIV Infections (immunology)</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (complications)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV Infections</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza Vaccines</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">During the influenza pandemic of 2009/10, the whole-virion, Vero-cell-derived, inactivated, pandemic influenza A (H1N1) vaccine Celvapan® (Baxter) was used in Austria. Celvapan® is adjuvant-free and was the only such vaccine at that time in Europe. The objective of this observational, non-interventional, prospective single-center study was to evaluate the immunogenicity and tolerability of two intramuscular doses of this novel vaccine in HIV-positive individuals.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22629330</PMID><DateCompleted><Year>2012</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>5</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.</ArticleTitle><Pagination><MedlinePgn>e36773</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0036773</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">During the influenza pandemic of 2009/10, the whole-virion, Vero-cell-derived, inactivated, pandemic influenza A (H1N1) vaccine Celvapan® (Baxter) was used in Austria. Celvapan® is adjuvant-free and was the only such vaccine at that time in Europe. The objective of this observational, non-interventional, prospective single-center study was to evaluate the immunogenicity and tolerability of two intramuscular doses of this novel vaccine in HIV-positive individuals.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">A standard hemagglutination inhibition (HAI) assay was used for evaluation of the seroconversion rate and seroprotection against the pandemic H1N1 strain. In addition, H1N1-specific IgG antibodies were measured using a recently developed ELISA and compared with the HAI results. Tolerability of vaccination was evaluated up to one month after the second dose. A total of 79 HIV-infected adults with an indication for H1N1 vaccination were evaluated. At baseline, 55 of the 79 participants had an HAI titer ≥1:40 and two patients showed a positive IgG ELISA. The seroconversion rate was 31% after the first vaccination, increasing to 41% after the second; the corresponding seroprotection rates were 92% and 83% respectively. ELISA IgG levels were positive in 25% after the first vaccination and in 37% after the second. Among the participants with baseline HAI titers <1:40, 63% seroconverted. Young age was clearly associated with lower HAI titers at baseline and with higher seroconversion rates, whereas none of the seven patients >60 years of age had a baseline HAI titer <1:40 or seroconverted after vaccination. The vaccine was well tolerated.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The non-adjuvanted pandemic influenza A (H1N1) vaccine was well tolerated and induced a measurable immune response in a sample of HIV-infected individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lagler</LastName><ForeName>Heimo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grabmeier-Pfistershammer</LastName><ForeName>Katharina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Touzeau-Römer</LastName><ForeName>Veronique</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Tobudic</LastName><ForeName>Selma</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ramharter</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wenisch</LastName><ForeName>Judith</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gualdoni</LastName><ForeName>Guido Andrés</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Redlberger-Fritz</LastName><ForeName>Monika</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Popow-Kraupp</LastName><ForeName>Theresia</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Rieger</LastName><ForeName>Armin</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Burgmann</LastName><ForeName>Heinz</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>05</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>04</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22629330</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0036773</ArticleId><ArticleId IdType="pii">PONE-D-11-23751</ArticleId><ArticleId IdType="pmc">PMC3357418</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2003 Dec 13;362(9400):1959-66</Citation><ArticleIdList><ArticleId IdType="pubmed">14683655</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS. 2011 Jan 14;25(2):177-83</Citation><ArticleIdList><ArticleId IdType="pubmed">21150561</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hyg (Lond). 1972 Dec;70(4):767-77</Citation><ArticleIdList><ArticleId IdType="pubmed">4509641</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1977 Dec;136 Suppl:S722-30</Citation><ArticleIdList><ArticleId IdType="pubmed">606797</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Jul 27;442(7101):448-52</Citation><ArticleIdList><ArticleId IdType="pubmed">16642006</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2006 Sep 16;368(9540):991-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16980114</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19357635</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2009 May 15;48(10):1402-12</Citation><ArticleIdList><ArticleId IdType="pubmed">19361304</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Jun 18;360(25):2605-15</Citation><ArticleIdList><ArticleId IdType="pubmed">19423869</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2009 Aug;9(8):493-504</Citation><ArticleIdList><ArticleId IdType="pubmed">19628174</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Aug 13;361(7):680-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19564631</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2009;14(41):19361</Citation><ArticleIdList><ArticleId IdType="pubmed">19883538</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Nov 12;361(20):1945-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19745214</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 Jan 28;362(4):370-2</Citation><ArticleIdList><ArticleId IdType="pubmed">20042746</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010;5(2):e9349</Citation><ArticleIdList><ArticleId IdType="pubmed">20186321</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2010 Mar 27;375(9720):1100-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20096450</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med Res Methodol. 2010;10:18</Citation><ArticleIdList><ArticleId IdType="pubmed">20210985</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Apr 30;28(20):3558-62</Citation><ArticleIdList><ArticleId IdType="pubmed">20307592</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2010;340:c2649</Citation><ArticleIdList><ArticleId IdType="pubmed">20508026</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS. 2010 Jun 1;24(9):F31-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20559034</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS. 2010 Aug 24;24(13):2142-3</Citation><ArticleIdList><ArticleId IdType="pubmed">20679764</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS. 2010 Sep 10;24(14):2187-92</Citation><ArticleIdList><ArticleId IdType="pubmed">20616698</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Oct 4;28(42):6811-20</Citation><ArticleIdList><ArticleId IdType="pubmed">20659520</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2011 Jan 1;52(1):138-46</Citation><ArticleIdList><ArticleId IdType="pubmed">21148532</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS. 2011 Jan 28;25(3):295-302</Citation><ArticleIdList><ArticleId IdType="pubmed">21157297</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2011 Feb;11(2):91-101</Citation><ArticleIdList><ArticleId IdType="pubmed">21168369</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2011 Jan 15;52(2):248-56</Citation><ArticleIdList><ArticleId IdType="pubmed">21288852</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Feb 11;29(8):1677-82</Citation><ArticleIdList><ArticleId IdType="pubmed">21199699</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(1):e16496</Citation><ArticleIdList><ArticleId IdType="pubmed">21304982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2011 Feb 26;377(9767):751-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21329971</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Kidney Dis. 2011 May;57(5):716-23</Citation><ArticleIdList><ArticleId IdType="pubmed">21349617</ArticleId></ArticleIdList></Reference><Reference><Citation>Transplantation. 2011 May 15;91(9):1031-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21358365</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Sep 16;29(40):6888-93</Citation><ArticleIdList><ArticleId IdType="pubmed">21803100</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(11):e27214</Citation><ArticleIdList><ArticleId IdType="pubmed">22087267</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Biol (Basel). 2003;115:63-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15088777</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C87 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000C87 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:22629330
|texte= Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:22629330" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |